Abstract Number: 2663 • ACR Convergence 2024
ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Background/Purpose: γδ T cells serve a role in immune surveillance and their capability to traffic to tissues is fundamental to their natural biology1. They are…Abstract Number: 0013 • ACR Convergence 2024
Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting immune cell responses that cause tissue damage in autoantibody-mediated diseases such as idiopathic inflammatory myopathies, lupus…Abstract Number: 0780 • ACR Convergence 2024
Deep B Cell Tissue Depletion Following Anti-CD19 CART Cells Therapy
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has proved potential for achieving long-term drug-free remission in patients with autoimmune diseases (AIDs). Its effectiveness likely…Abstract Number: 1750 • ACR Convergence 2024
Safety and Preliminary Efficacy of CD19 CAR-T Cell Treatment in Rheumatic Disease – Data from the First Part of the Phase I/II CASTLE Basket Study
Background/Purpose: Systemic autoimmune diseases are based on an aberrant activation of B cells. Autologous CD19 chimeric antigen receptor (CAR) T cells allow deep depletion of…Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…Abstract Number: 0014 • ACR Convergence 2024
Phenotypic Validation of Humanized IgA1 and CD89 Transgenic Mice as a Model for IgA Nephropathy-Like Autoimmune Disease
Background/Purpose: The etiology of IgA nephropathy (IgAN) remains only partly understood, but the presence of IgA antibodies together with the myeloid IgA-receptor FcαRI/CD89 complexes in…Abstract Number: 0786 • ACR Convergence 2024
First Analyses of Transcriptomic Changes in the Skin of SSc Patients upon CD19-targeting CAR T Cell Therapy
Background/Purpose: CD19-targeting CAR T cells showed remarkable improvements of modified Rodnan skin score in SSc patients within 6 months after treatment and stable reduction afterwards…Abstract Number: 1751 • ACR Convergence 2024
Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells
Background/Purpose: The autoreactive B cell compartment in systemic lupus erythematosus (SLE) is characterized by expansion of B cells expressing immunoglobulin heavy variable gene 4-34 (IGHV4-34)…Abstract Number: 0016 • ACR Convergence 2024
Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology
Background/Purpose: Germinal centers (GC) are specialized lymphoid structures found within the B cell follicles of secondary lymphoid tissue formed following infection or immunization. They are…Abstract Number: 0837 • ACR Convergence 2024
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
Background/Purpose: Available drugs to treat autoimmune diseases are indiscriminate, suppressing self-reactive and protective immune responses alike. This lack of therapeutic precision results in infection and…Abstract Number: 1752 • ACR Convergence 2024
T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus
Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of…Abstract Number: 0018 • ACR Convergence 2024
Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Background/Purpose: Autologous CD19-directed CAR-T cell therapy has been shown to eradicate aberrant B cells leading to durable clinical responses in SLE patients (Müller 2024; Wang 2024). However, autologous CAR-T cell…Abstract Number: 0876 • ACR Convergence 2024
C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases
Background/Purpose: B cells are pivotal in autoimmune disease pathogenesis as they produce autoantibodies and undergo aberrant maturation processes, and B-cell dysregulation and the production of…Abstract Number: 1753 • ACR Convergence 2024
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…Abstract Number: 0019 • ACR Convergence 2024
A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles
Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating clinical efficacy in various autoimmune disease indications. Despite…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 17
- Next Page »